Fostemsavir (Rukobia ®). HTA ID: 23018

Assessment Status Rapid Review Complete
HTA ID 23018
Drug Fostemsavir
Brand Rukobia ®
Indication Fostemsavir (Rukobia ®) in combination with other antiretrovirals, is indicated for the treatment of adults with multidrug resistant HIV-1 infection for whom it is otherwise not possible to construct a suppressive anti-viral regimen.
Assessment Process
Rapid review commissioned 27/03/2023
Rapid review completed 20/04/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of fostemsavir compared with the current standard of care, on the basis of the proposed price. *

*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.